Sign in

Private company

Deciphera Pharmaceuticals, Inc.

In its 2024 annual report the company says: “We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We wholly own QINLOCK and all of our drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China. In addition to QINLOCK, we have developed a robust pipeline of novel drug candidates using our switch-control kinase inhibitor platform, including vimseltinib and DCC-3116.”5 It is headquartered in Waltham, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersWaltham, United States2
  • Incorporated inDE3
  • Business address200 Smith Street, Waltham, Ma 024513
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI529900QR4WAPYY0CBF252
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 64978322

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, we design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through our patient-inspired approach, we seek to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, our switch-control tyrosine kinase inhibitor, was discovered using our proprietary drug discovery platform and designed for the treatment of GIST. QINLOCK is approved in Australia, Canada, China, the European Union (EU), Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, the U.K., and the U.S. for t…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-129.1%Operating margin6
-119.3%Net margin7
21.9%Revenue growth, 20236
-55.5%Return on equity6
-$147.5MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue1¢$3.7M
  • Research and development62¢$234.1M
  • Selling, general and admin36¢$136.5M
  • Income tax0¢$431.0K

Out of $163.4M in revenue.67 The company lost money this year.

Financial statements

Revenue8910116$163.4M in 2023
0$50.0M$100.0M$150.0M$200.0M2017: $0$020172018: $0$020182019: $25.0M$25.0M20192020: $42.1M$42.1M2020+68%2021: $96.1M$96.1M2021+128%2022: $134.0M$134.0M2022+39%2023: $163.4M$163.4M2023+22%
Operating income12910116-$211.0M in 2023+314% since 2017
-$400.0M-$300.0M-$200.0M-$100.0M02017: -$50.9M-$50.9M20172018: -$104.1M-$104.1M2018+104%2019: -$200.7M-$200.7M2019+93%2020: -$271.2M-$271.2M2020+35%2021: -$300.1M-$300.1M2021+11%2022: -$182.7M-$182.7M2022−39%2023: -$211.0M-$211.0M2023+15%
Net income129101167-$194.9M in 2023+288% since 2017
-$300.0M-$200.0M-$100.0M02017: -$50.3M-$50.3M20172018: -$99.9M-$99.9M2018+99%2019: -$192.3M-$192.3M2019+93%2020: -$266.5M-$266.5M2020+39%2021: -$300.0M-$300.0M2021+13%2022: -$178.9M-$178.9M2022−40%2023: -$194.9M-$194.9M2023+9%
Fiscal year2017201820192020202120222023
Revenue$08$09$25.0M10$42.1M11$96.1M6$134.0M6$163.4M6
Cost of revenue$09$010$225.0K11$2.9M6$8.8M6$3.7M6
Research and development$39.5M12$82.9M9$157.6M10$199.0M11$257.0M6$187.8M6$234.1M6
Selling, general and admin$21.2M9$68.1M10$114.1M11$136.3M6$120.2M6$136.5M6
Operating expenses$396.2M6$316.8M6$374.3M6
Operating income-$50.9M12-$104.1M9-$200.7M10-$271.2M11-$300.1M6-$182.7M6-$211.0M6
Interest$95.0K12$84.0K9$67.0K10$010$010
Income before tax-$300.0M6-$178.2M6-$194.5M6
Income tax$015$09$010$011$06$722.0K6$431.0K6
Net income-$50.3M12-$99.9M9-$192.3M10-$266.5M11-$300.0M6-$178.9M6-$194.9M7
Earnings per share-$4.7811-$5.166-$2.376-$2.296
Earnings per share (diluted)-$4.7811-$5.166-$2.376-$2.296
Shares (weighted, basic)58.1M shares675.5M shares685.1M shares6
Shares (weighted, diluted)58.1M shares675.5M shares685.1M shares6

Compare Deciphera Pharmaceuticals, Inc. with another company

Corporate structure

Deciphera Pharmaceuticals, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Deciphera Pharmaceuticals, Inc.

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 15, 2022)
  • BRAIDWELL LP Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Redmile Group, LLC Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 14, 2024 (4 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 13, 2024 (3 filings since Feb 9, 2022)
  • James E. Flynn Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 12, 2024 (5 filings since Nov 10, 2021)
  • Brightstar Associates LLC Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 9, 2024 (2 filings since Feb 8, 2023)
  • Goldman Sachs Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 6, 2024 (3 filings since Feb 2, 2022)
  • BlackRock Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Jan 26, 2024 (3 filings since Feb 3, 2022)
  • State Street Corporation Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Jan 23, 2024 (4 filings since Jan 10, 2022)
  • Bank of America Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 14, 2023 (2 filings since Jan 31, 2022)
  • Franklin Templeton Investments Filed SC 13G/A on Deciphera Pharmaceuticals, Inc., latest Feb 3, 2022
  • Deciphera Pharmaceuticals, Inc. Waltham, Massachusetts, United States
    • Deciphera Pharmaceuticals Securities Corporation Subsidiary · Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Deciphera Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$17.6M6 Dec 31, 2023$16.8M6 Dec 31, 2022+4.9%
Accumulated depreciation$12.2M6 Dec 31, 2023$10.1M6 Dec 31, 2022+21.0%
Property and equipment, net$5.4M6 Dec 31, 2023$6.7M6 Dec 31, 2022−19.2%
Operating-lease assets (leased space)$32.1M6 Dec 31, 2023$36.5M6 Dec 31, 2022−12.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$83.5M6 Dec 31, 2023$64.7M6 Dec 31, 2022+29.0%
Marketable securities, current$222.7M6 Dec 31, 2023$259.7M6 Dec 31, 2022−14.3%
Marketable securities, non-current$46.7M6 Dec 31, 2023$14.6M6 Dec 31, 2022+221.0%
Debt securities available for sale$269.4M6 Dec 31, 2023$274.3M6 Dec 31, 2022−1.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$21.2M6 Dec 31, 2023$20.6M6 Dec 31, 2022+3.2%
Raw materials$4.9M6 Dec 31, 2023$6.8M6 Dec 31, 2022−27.9%
Work in process$18.3M6 Dec 31, 2023$11.1M6 Dec 31, 2022+64.1%
Finished goods$3.0M6 Dec 31, 2023$2.6M6 Dec 31, 2022+14.1%

Leadership

Who has led Deciphera Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Douglas Taylor2019
  2. Steven L. Hoerter2019–2024

President

  1. Michael Douglas Taylor2019
  2. Steven L. Hoerter2019–2024

Chief financial officer

  1. Thomas Patrick Kelly2017–2024
20202025
Board members and other officers (18)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Deciphera Pharmaceuticals Securities Corporation Massachusetts4
  • Deciphera Pharmaceuticals, LLC Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Deciphera Pharmaceuticals, LLCSep 29, 2015 to Aug 15, 20173

Timeline

  1. Jun 11, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer36
  2. Apr 29, 20248-K Entered a material agreement; Other events37
  3. Feb 6, 20248-K Results of operations38
  4. Jan 8, 20248-K Results of operations; Other events39
  5. Oct 30, 20238-K Results of operations; Other events40
  6. Aug 9, 20238-K Results of operations41
  7. Aug 3, 20238-K Executive or director change42
  8. Jun 22, 20238-K Shareholder vote43
  9. May 3, 20238-K Results of operations44
  10. Feb 7, 20238-K Results of operations45
  11. Jan 20, 20238-K Entered a material agreement46
  12. Jan 18, 20238-K Other events47
  13. Mar 20, 2019New chief executive Steven L. Hoerter becomes CEO17
  14. Feb 1, 2019New chief executive Michael Douglas Taylor becomes CEO16

Calendar

When it reported results

  1. Feb 6, 2024Reported quarterly or annual results38
  2. Jan 8, 2024Reported quarterly or annual results39
  3. Oct 30, 2023Reported quarterly or annual results40
  4. Aug 9, 2023Reported quarterly or annual results41
  5. May 3, 2023Reported quarterly or annual results44
  6. Feb 7, 2023Reported quarterly or annual results45
  7. Jan 3, 2023Reported quarterly or annual results48
  8. Nov 3, 2022Reported quarterly or annual results49

Drug trials and FDA: coming up

  1. Mar 2027Phase 1/2 trial readout expected Phase 1/2 trial of Inlexisertib and Ripretinib in GIST: primary completion expected Mar 2027 (ClinicalTrials.gov NCT05957367).50

Drug trials and FDA: recently

  1. Jun 26, 2026FDA approved a new use FDA approved an efficacy supplement for Romvimza (vimseltinib), a new use or patient group (NDA 219304, supplement 2).51
  2. Feb 14, 2025FDA approval FDA approved Romvimza (vimseltinib), a new molecular entity, priority review (NDA 219304).52

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

252 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 29 major events, 118 insider forms, 33 large holders, 61 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Jun 21, 202415-12G EDGAR
  3. Jun 13, 2024EFFECT EDGAR
  4. Jun 11, 2024S-8 POS EDGAR
  5. Jun 11, 2024S-8 POS EDGAR
  6. Jun 11, 2024S-8 POS EDGAR
  7. Jun 11, 2024S-8 POS EDGAR
  8. Jun 11, 2024S-8 POS EDGAR
  9. Jun 11, 2024S-8 POS EDGAR
  10. Jun 11, 2024S-8 POS EDGAR
  11. Jun 11, 2024S-8 POS EDGAR
  12. Jun 11, 2024POS AM EDGAR
  13. Jun 11, 2024POSASR EDGAR
  14. Jun 11, 20248-K EDGAR
  15. Jun 11, 2024SC 14D9/A EDGAR
  16. Jun 11, 2024SC TO-T/A EDGAR
  17. Jun 11, 20244 EDGAR
  18. Jun 11, 20244 EDGAR
  19. Jun 11, 20244 EDGAR
  20. Jun 11, 20244 EDGAR

The 252 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

53 open-market trades by officers, directors and large owners since October 2021: 4 buys and 49 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 16, 2024Kelly Thomas PatrickChief Financial OfficerSale3,010$15.62$47.0KForm 4
Feb 16, 2024Martin Daniel C.Chief Commercial OfficerSale2,267$15.62$35.4KForm 4
Feb 16, 2024Sherman Matthew LEVP & Chief Medical OfficerSale2,615$15.62$40.8KForm 4
Feb 16, 2024Pitman JamaSVP, Chief Development OfficerSale2,267$15.62$35.4KForm 4
Jan 16, 2024Sherman Matthew LEVP & Chief Medical OfficerSale2,435$14.47$35.2KForm 4
Jan 16, 2024Pitman JamaSVP, Chief Development OfficerSale1,624$14.47$23.5KForm 4
Jan 16, 2024Kelly Thomas PatrickChief Financial OfficerSale2,435$14.47$35.2KForm 4
Jan 16, 2024Martin Daniel C.Chief Commercial OfficerSale1,624$14.47$23.5KForm 4
Dec 13, 2023Hoerter Steven L.President and CEOSale30,664$15.37$471.3KForm 4
Dec 13, 2023Pitman JamaSVP, Chief Development OfficerSale1,662$15.37$25.5KForm 4
Dec 13, 2023Kelly Thomas PatrickChief Financial OfficerSale2,792$15.37$42.9KForm 4
Dec 13, 2023Martin Daniel C.Chief Commercial OfficerSale1,727$15.37$26.5KForm 4
Dec 13, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,792$15.37$42.9KForm 4
Nov 30, 2023Martin Daniel C.Chief Commercial OfficerSale17,801$12.57$223.8KForm 4
Oct 30, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,360$12.02$28.4KForm 4
Oct 30, 2023Pitman JamaSVP, Chief Development OfficerSale1,407$12.02$16.9KForm 4
Oct 30, 2023Martin Daniel C.Chief Commercial OfficerSale1,407$12.02$16.9KForm 4
Oct 30, 2023Kelly Thomas PatrickChief Financial OfficerSale2,316$12.02$27.8KForm 4
Oct 30, 2023Hoerter Steven L.President and CEOSale21,573$12.02$259.3KForm 4
Oct 2, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,942$12.68$37.3KForm 4

All 53 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Deciphera Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDeciphera Pharmaceuticals, Inc.1
  • CIK0001654151
  • Employer ID (EIN)20-02997251
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address200 Smith Street, Waltham, MA 024511
  • Phone781-209-64001
  • Shares outstanding86,475,972 as of May 6, 20247
  • Public float$777.1M as of Jun 30, 20236
  • On EDGAR sinceSep 29, 20151
  • Filings580 in all: 4 (273), 8-K (78), SC 13G/A (29), 3 (24), 10-Q (20), SC 13G (17), UPLOAD (12), CORRESP (10)1
    All 48 form types

    424B5 (9), S-8 (8), S-8 POS (8), 10-K (7), DEF 14A (7), DEFA14A (7), EFFECT (6), S-1/A (5), 3/A (4), SC 13D/A (4), 4/A (3), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), 424B4 (2), ARS (2), D (2), DRS (2), DRS/A (2), DRSLTR (2), POS AM (2), POSASR (2), S-1 (2), S-1MEF (2), S-3 (2), S-3ASR (2), SC 13D (2), SC TO-C (2), 144 (1), 15-12G (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), D/A (1), PRE 14A (1), PRER14A (1), S-3MEF (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 7, 2024
    Quarterly report (10-Q) May 10, 2024
    Proxy statement (DEF 14A) Apr 25, 2024
    Latest 8-K (8-K) Jun 11, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63